A molecular mechanism to explain reduced KAI1 expression in invasive and metastatic tumour cells remains elusive. In this report, we extend an earlier study in bladder cells to confirm that a 76 bp region of the KAI1 promoter (residues À922 to À847), with binding motifs for p53, AP1 and AP2, is required for high level activity of a KAI1 reporter in prostate cancer cell lines. Gel shift and supershift experiments supported binding of p53, junB and heterodimers of AP2a/AP2c or AP2b/AP2c to this sequence. Introduction of mutations into specific motifs demonstrated an essential requirement for p53 and junB to reporter activity, and that functional synergy between these two factors enhanced activity. A further elevation of reporter activity required AP2. Roles of individual p53, junB and AP2 proteins, as well as functional synergy between p53 and junB, were confirmed in transfection experiments. Western blotting analysis showed that an absence of wild-type p53, and/or a loss of junB and AP2 protein expression, correlated with downregulation of KAI1 mRNA levels in a series of prostate cancer cell lines. A loss of p53 function and/or expression of junB, combined with reduced expression of specific AP2 proteins may underly downregulated KAI1 expression in tumour cells.
Introduction
Altered expression of the KAI1 metastasis suppressor gene (Dong et al., 1995) in a wide range of human tumours is now well established (reviewed in Jackson and Marreiros, 2004) . However, the underlying cause for loss of KAI1 expression in advanced tumours and tumour cell lines remains unknown. Available evidence suggests that mechanisms including loss of heterozygosity at the KAI1 locus on human chromosome 11p11.2, gene or promoter mutation and promoter hypermethylation are not responsible (Dong et al., 1996; Tagawa et al., 1999; Liu et al., 2000; Miyazaki et al., 2000; Sekita et al., 2001) . Another possible explanation is that loss of KAI1 expression might reflect altered transcriptional regulation. A p53-binding motif has been identified within the KAI1 promoter, suggesting that KAI1 might be a cellular target of p53 (Mashimo et al., 1998) . However, results from studies using tissue samples and tumour cell lines have so far indicated that a loss of p53 function is unlikely to be the only determinant of KAI1 mRNA levels (Lombardi et al., 1999; Duriez et al., 2000; Miyazaki et al., 2000; Ow et al., 2000; Schindl et al., 2001; Jackson et al., 2002 Jackson et al., , 2003 .
The proximal region of the KAI1 promoter contains potential binding sites for several transcription factors including AP2, NF-kB, AP1 and Sp1, some or all of which may be responsible for epithelial-and tissuespecific expression of KAI1 (Dong et al., 1997) . To date, direct evidence that these binding sites are functional is limited, and their contribution to KAI1 transcription unknown. A role for NF-kB was suggested from a study investigating TNFa-induced expression of KAI1 mRNA in PC-14 lung cancer cells (Shinohara et al., 2001) , but the significance of this result is unclear because upregulation of KAI1 mRNA levels was not accompanied by TNFa-induced binding of NF-kB to its putative motif within the KAI1 promoter. Elevation of KAI1 expression in response to etoposide in prostate cancer cells and cotransfection studies have also provided some support for c-jun (Mashimo et al., 2000) , while phorbol ester induction of KAI1 expression has implicated c-fos and c-jun (Akita et al., 2000) . Overall, these data have provided a useful beginning towards identification of factors regulating KAI1 transcription, but the overall mechanism of transcriptional regulation and how this might be affected in tumour cells remains poorly understood.
In a previous study, we reported that a 76 bp promoter sequence between residues À922 and À847 upstream of the transcription start site, and containing binding motifs for AP2, p53 and AP1 was essential for high level KAI1 promoter activity in bladder cancer cells (Marreiros et al., 2003) . The aim of this study was to further examine the importance of this promoter region to KAI1 transcription by extending our investigations to prostate cells, by identifying which members of the AP2 and AP1 families are specifically involved in binding, and to characterize more precisely the relationship between these different factors in regulating KAI1 promoter activity.
Results

KAI1 mRNA levels in prostate cell lines
To identify a suitable model for studying KAI1 transcription, we examined endogenous KAI1 mRNA levels in several prostate cell lines, including an immortalized, nontumourigenic line (PZ-HPV-7) and nine lines derived from cancers. Consistent with previous studies (White et al., 1998; Jackson et al., 2002; Lijovic et al., 2002) , highest levels of KAI1 mRNA were present in PZ-HPV-7 (Figure 1 ). Lower, but clearly detectable mRNA expression was detected in LNCaP and its derivatives C4 and C4-2, as well as in PC3. Little or no KAI1 mRNA was expressed in DU145, PC3M, PC3MM2, MDA-PCa-2A or MDA-PCa-2B. Thus, we reasoned that PZ-HPV-7 cells should contain all factors required for regulating KAI1 transcription, and used this line to examine sequences important for promoter activity.
Importance of the À922/À847 promoter region to KAI1 expression in prostate cancer cells Based on previous data (Marreiros et al., 2003) , reporter plasmids spanning À1118/À36 to À846/À36 bp of upstream KAI1 promoter sequence ( Figure 2 ) were transfected into PZ-HPV-7. High level activity was obtained with the reporter spanning À1118/À36 and maintained if the sequence was deleted by 49 bp (À1069/ À36) or 196 bp (À922/À36). Reporter activity was not increased by having promoter sequences upstream of À1118 (data not shown). Deletion of promoter sequences between À922/À36 and À846/À36 (removal of AP2-, p53-and AP1-binding motifs) resulted in >80% drop in activity, confirming the importance of this sequence. Removal of sequences downstream of À846 decreased low level activity to that of the control plasmid (pBLCAT3) and was consistent with recent data showing that the proximal 846 bp supports basal activity of the KAI1 promoter (Gao et al., 2003) .
To assess if the À922/À847 promoter region was generally important for activity, we transfected cells with reporters in which this sequence was either present (p-1118KAICAT) or absent (p-846KAICAT). The p-1118KAICAT construct was used to ensure that the complete binding motifs for AP2, p53 and AP1 and flanking regions were present in the reporter. Data summarized in Table 1 showed that in lines with clearly detectable endogenous KAI1 mRNA, the presence of À922/À847 in the reporter increased activity 2-5.5-fold compared with p-846KAICAT. In contrast, activities of p-1118KAICAT in cell lines with little or no detectable endogenous KAI1 mRNA were similar to that of p-846KAICAT. These data supported the idea that binding of factors to the À922 to À847 region of the KAI1 promoter and which were present or functional in PZ-HPV-7, PC3, LNCaP, LNCaP-C4 and LNCaP-C4-2 but not in PC3M, PC3MM2, DU145, MDAPCa-2A and MDA-PCa-2B, might be important determinants of KAI1 mRNA levels. Interestingly, low levels of p-846KAICAT versus pBLCAT3 activity in PC3M, PC3MM2, MDA-PCa-2A and MDA-PCa-2B cell lines suggested that reduced activity from sequences within the proximal 846 bp might also contribute to a lower overall expression of KAI1 mRNA in these cell lines.
Confirmation that AP2, p53 and AP1 bind to the À922/À847 region of the KAI1 promoter Gel shifts with oligonucleotide probes of AP2-, p53-and AP1-binding motifs from the À922/À847 region of the KAI1 promoter ( Figure 3a ) were used to verify that Figure 1 KAI1 and GAPDH mRNA levels in prostate cancer cell lines. Total RNA was isolated from cultured cells, converted to cDNA and used in PCR reactions as described in Materials and methods. In preliminary experiments, the linear phase of PCR amplification was determined for each primer set. Thus, GAPDH (G) levels were assessed after 21 cycles, and KAI1 levels after 27, 31 and 35 cycles (
). PZ-HPV-7 showed highest levels of KAI1 mRNA, with lower levels present in LNCaP, LNCaP-C4, LNCaP-C4-2 and PC3. Very low levels of KAI1 mRNA were present in DU145, PC3M, PC3MM2, MDA-PCa-2A and MDA-PCA-2B factors binding these motifs were present in nuclear extracts of PZ-HPV-7. Specificity of binding was tested in competition experiments using excess unlabelled oligonucleotide carrying wild-type or mutated sequences, and specific versus nonspecific antibodies.
A labelled probe corresponding to the AP2-binding motif (À907/À899 in promoter) produced several retarded bands ( Figure 3b, lane 2) . Specificity of the largest complex was confirmed by competition with excess unlabelled probe (Figure 3b , lane 3), but not a probe with mutations to inhibit AP2 binding ( Figure  3a , b, lane 4). The presence of AP2 in this complex was shown by competition with a commercially available consensus AP2 motif (Figure 3b , lane 5), but not with a p53 consensus motif (Figure 3b , lane 6). To further verify involvement of AP2 and to identify which of three, related human AP2 proteins (AP2a, AP2b, AP2g; Hilger-Eversheim et al., 2000; Zhao et al., 2001 ) was responsible for complex formation, we performed supershift experiments using an antibody crossreactive to all AP2 proteins, as well as isoform-specific antibodies. In addition to the specific complex described above, under extended incubation times used in supershift experiments (see Materials and methods), we noted a second major complex (AP2#; Figure 3b , lane 7). Formation of both complexes was strongly inhibited by an antibody to all AP2 proteins, but not by an antibody to Jun proteins (Figure 3b, lanes 11 and 12) . An antiAP2g-specific antibody was as effective as our general AP2 antibody in inhibiting formation of both AP2 complexes (Figure 3b , lane 10), indicating that AP2g was a component of both complexes. Formation of the lower, AP2# complex was only poorly inhibited by AP2a-specific or AP2b-specific antibodies (Figure 3b , lanes 8 and 9). On the other hand, there was clear inhibition of the upper complex by these two antibodies, but this inhibition was consistently less effective than that caused by either the AP2g-specific or general AP2 antibodies. Overall, these data suggested that the lower AP2# complex, which formed only after extended incubation times, was most probably composed of AP2g homodimers, but that the more readily formed upper complex consisted of AP2a/AP2g and AP2b/AP2g heterodimers. Figure 2 KAI1 reporter activity in transiently transfected PZ-HPV-7. The KAI1 promoter reporters used are shown, with transcription factor-binding motifs within the À922/À847 region indicated. CAT activity was dramatically decreased by removal of sequences between À922 and À847. Data presented are expressed as mean7s.e. derived from three independent experiments, after normalization to the activity obtained from a pBLCAT3 empty vector control Several complexes were also obtained with the oligonucleotide encompassing the p53 motif (À894/ À864 in promoter; Figure 3c , lane 2). Specificity of the largest complex (p53) was confirmed by competition with excess unlabelled probe and consensus oligonucleotide ( Figure 3c , lanes 3 and 5), but not by a mutated oligonucleotide or an AP2 consensus oligonucleotide ( Figure 3c , lanes 4 and 6). Similar to results with AP2, extended incubation times in supershift experiments resulted in formation of further complexes ( Figure 3c , p53# and p53*). Reduced formation of p53 and p53* complexes was observed with a p53-specific but not Jun-specific antibody ( Figure 3c , lanes 7-9). Given that the PZ-HPV-7 line was generated by transformation of normal prostatic peripheral zone epithelial cells with oncogenic HPV type 18, and expresses HPV E6 protein (Weijerman et al., 1994) , one might predict that these cells should not possess functional p53 protein due to degradation mediated by viral E6 protein (Scheffner et al., 1990) . However, our gel shift data are consistent with previous studies showing functional p53 in cells transformed by oncogenic HPV (May et al., 1991; Li et al., 1992; Butz et al., 1995; Jackson et al., 2002) .
A major and two minor complexes were formed by a probe containing the AP1 motif (À872/À852 in promoter; Figure 3d , lane 2). Formation of the major complex was ablated by unlabelled probe and consensus AP1 oligonucleotide ( Figure 3d , lanes 3 and 5), but not by a mutated motif or AP2 consensus oligonucleotide ( Figure 3d , lanes 4 and 6). Binding of AP1 was confirmed by supershifting of the complex by antibody to all Jun proteins but not the AP2 antibody (Figure 3d , lanes 21 and 22). AP1 is formed of homo-and heterodimers including jun (c-jun, junB, junD) and fos (c-fos, FosB, Fra-1 and Fra-2 ) proteins (Chinenov and Kerppola, 2001) , and can also interact with members of other protein families, including the ATF/CREB family (Chinenov and Kerppola, 2001 ). Of 13 AP1/ATF family proteins investigated (Figure 3d, , only the junB antibody supershifted the specific AP1 complex (Figure 3d , lane 9), suggesting that AP1 binding to the KAI1 promoter in nuclear extracts of PZ-HPV-7 cells was formed of junB homodimers.
Functional analysis of the À922/À847 region of the KAI1 promoter
To examine functional importance of AP2-, p53-and AP1-binding motifs to KAI1 promoter activity, we generated reporter plasmids in which mutations used in gel shift experiments were introduced into individual motifs or various combinations of motifs ( Figure 4a ). Mutated reporters were transfected into PZ-HPV-7 and their activities compared to that of a reporter with normal promoter sequence (p-922KAICAT). Mutations in either the p53 (pKAImutp53) or AP1 (pKAImutAP1) motifs each resulted in a dramatic 85-90% reduction in reporter activity, implying critical requirements of p53 and AP1 motifs for promoter activity. In contrast, in six independent experiments, mutation of the AP2 motif (pKAImutAP2) only reduced reporter activity by Figure 4a ), suggesting that the AP2 motif was not essential, but contributed to full promoter activity. Further support for involvement of the AP2 motif was obtained by deletion of the AP2 motif, but not p53 or AP1 motifs (p-892KAICAT). Activity of the truncated reporter was decreased by more than 70% compared with the wild-type construct (Figure 4b ). The notion that three motifs were required for full promoter activity was emphasized using pKAImutP, where all three were mutated, and where reporter activity was almost completely lost (Figure 4a ). Using reporters with two of three motifs mutated allowed examination of the importance of each remaining normal motif (Figure 4a) . Thus, plasmids pKAImutQ (mutated AP2 and p53, normal AP1) and pKAImutR (mutated AP2 and AP1, normal p53) each possessed low level reporter activity (11 and 13% of p-922KAICAT, respectively). Of note, activity from pKAImutAP2 (mutated AP2, normal AP1 and p53; 63% of p-922KAICAT activity) was more than double combined activities of pKAImutQ and pKAImutR, suggesting a possible synergistic effect between factors binding p53 and AP1 motifs. Activity of pKAImutS (mutated p53 and AP1, normal AP2 motif; 7% p-922KAICAT activity) was also higher than that of pKAImutP (3% of p-922KAICAT), suggesting that binding of AP2 alone permitted weak reporter activity. Taken together, these data supported a model in PZ-HPV-7 cells, whereby binding of p53, AP1 and AP2 to their respective motifs, each permitted low level promoter activity (where the effect of p53 ¼ AP1bAP2). Importantly, binding of p53 and AP1 were essential for activity, and a synergistic interaction between these two factors dramatically enhanced activity. Full promoter activity, however, involved a further contribution from the binding of AP2.
Relationship between AP2, p53 and junB and KAI1 mRNA levels in prostate cancer cell lines
In agreement with our gel shift data, and the importance of p53, junB and AP2 to KAI1 promoter activity, Western blotting analysis of nuclear extracts from PZ-HPV-7 confirmed expression of p53, junB and all AP2 isoforms ( Figure 5 ). To determine if our model might be generally applicable, we extended analysis to other prostate cancer cell lines. LNCaP, its derivatives C4 and C4-2, as well as PC3, express similar levels of KAI1 mRNA which are lower than PZ-HPV-7 (Figure 1 ; summarized in Figure 5 ). All three LNCaP-derived lines had low levels of wild-type (Jackson et al., 2002) p53 and AP2g levels similar to PZ-HPV-7, but AP2a, AP2b and junB were not detected ( Figure 5 ). These data supported a possibility that low levels of KAI1 mRNA in these lines were mainly due to p53, reflecting a loss of functional synergy between p53 and junB, and the absence of AP2 proteins capable of transactivating the KAI1 promoter (AP2a and AP2b). On the other hand, +++++ ++ ++ ++ ++ + + + + Figure 5 Western blotting analysis of AP2, AP1 and p53 proteins in nuclear extracts of prostate cancer cell lines. Equal amounts of nuclear extract (10 mg protein) were separated in 10% SDS-PAGE and transferred to nitrocellulose membranes. Individual AP2 proteins, junB and p53 were detected by specific antibodies. Since nuclear extracts were used, levels of a nonspecific protein detected by the AP2a antiserum were used to show equivalent loading, as previously described (see for example, Ruiz et al., 2004) . Relative KAI1 mRNA levels within each cell line are indicated, and were obtained by scanning densitometry analysis of ethidium bromide-stained agarose gels such as that in Figure 1 . KAI1/GAPdH ratios were obtained for each cell line, at 31 cycles (KAI1) or 21 cycles (GAPDH) of amplification, and then normalized to the ratio for PZ-HPV-7 cells ) and all AP2 proteins (AP2a levels lower than in PZ-HPV-7). We suggest that the low level of KAI1 mRNA in PC3 reflects activities of junB (in the absence of p53), with AP2a/AP2g and AP2b/AP2g. The PC3 derivative, PC3MM2, has very low levels of endogenous KAI1 mRNA compared with PC3 (Figure 1 ). This is consistent with absence of p53 function combined with a further lack of AP2g preventing formation of AP2 heterodimers, thus KAI1 mRNA levels reflect the action of junB alone. DU145 cells also express little KAI1 mRNA (Figure 1 ). These cells contained high levels of mutant p53 (P223L and V274F; Jackson et al., 2002) , levels of junB and AP2g similar to PZ-HPV-7, but lower levels of AP2b and no AP2a ( Figure 5 ). KAI1 mRNA expression in DU145 may again reflect lack of p53 function combined with reduced formation of AP2a/AP2g and AP2b/AP2g.
MDA-PCa-2A and MDA-PCa-2B had barely detectable levels of p53 (wild-type sequence; van Bokhoven et al., 2003) and no AP2a or AP2b ( Figure 5 ). Additionally, MDA-PCa-2A had very low levels of junB and apparently truncated rather than full-length AP2g, whereas MDA-PCa-2B completely lacked junB but had normal levels of full-length AP2g. Consistent with our model, MDA-PCa-2A cells had little or no endogenous KAI1 mRNA (Figure 1 ). Since the profile of MDA-PCa-2B was similar to that of LNCaP, we expected the KAI1 mRNA level in this line to be more similar to that in LNCaP, rather than that of MDAPCa-2A (Figure 1) . The reasons for this discrepancy are unclear, but conceivably it may reflect loss of downstream p53 function. A similar observation has been made for the BL28 bladder cancer cell line, where p53 with wild-type sequence cannot induce a normal response to DNA damage (Ribeiro et al., 1997) or activate promoters with p53-binding motifs (Jackson et al., 2002) .
Taken together, our data supported the idea that a combination of p53, junB, AP2a/g and AP2b/g might be a major determinant of KAI1 mRNA levels in prostate cancer cells.
Activation of the KAI1 promoter in prostate cells by transfected AP2, AP1 and p53 proteins
We took advantage that several of our prostate lines lacked expression of individual factors to further assess the contributions of p53, AP1 (junB) and AP2 (a, b, or g) proteins to KAI1 promoter activity using transfection assays with plasmid vectors expressing each protein. LNCaP cells were chosen because they have no detectable AP2a, b or junB (Figure 6 ), and PC3 because they have no p53. Overall, similar results were obtained with each cell type, but for brevity, data for LNCaP are presented. We initially focused on p53 and junB because our data suggested an essential requirement for these two proteins and we had preliminary evidence for possible functional synergy. Results showed that p53 ( Figure 6a ) and junB ( Figure 6b ) each induced modest (p53, 6.5-fold; junB, 2.3-fold) reporter activation. We anticipated that cotransfection of the two proteins might induce synergistic elevation of reporter activity. Owing to different base vectors used in construction of each plasmid, in this and subsequent experiments involving AP2 proteins described below, it was necessary to repeat transfections with individual vectors using appropriate combinations of each empty vector as control. Under these revised transfection conditions, p53 retained (B7.5-fold) activation of the reporter but junB had no effect (Figure 6c) . Furthermore, cotransfection using 1.0 mg of each expression vector consistently resulted in reporter activity similar to that of p53 alone (Figure 6c ). One possible explanation for these data might involve competition by the CMV promoter within the p53 vector, for factors needed by the SV promoter to transcribe junB, resulting in poor expression of junB in cotransfected cells. To test this possibility, we reduced the amount of p53 plasmid and increased the amount of junB plasmid used in transfections, such that the ratio of junB plasmid to p53 plasmid increased from 1 : 1 to 3 : 1. Under these conditions (Figure 6d ), we saw less reporter activation by p53 (B3.1 Â ) and a low but consistent elevation of reporter activity by junB (B1.5 Â ). Importantly, cotransfection of p53 with junB now elevated reporter activity almost eightfold (almost double the additive effect of p53 and junB individually), suggesting that p53 and junB can synergize to enhance reporter activity. Western blotting analysis of nuclear extracts from transfected cells confirmed our initial notion. Using a 1 : 1 ratio of p53 plasmid to junB plasmid, there was increased expression of p53 protein compared with empty vector-transfected control cells, but no junB protein could be detected Figure 6e (lanes 1 and 2). However, with a junB to p53 plasmid ratio of 3 : 1, the level of detected p53 decreased and transfected junB protein was now clearly visible ( Figure 6e, lane 3) .
We also examined the ability of individual AP2 factors to activate the KAI1 reporter. Data summarized in Figure 6f showed that AP2b (average 2.2-fold) clearly activated the reporter, AP2a induced a small but consistent rise (1.4-fold) in activity, but that AP2g alone had no effect. In separate experiments, we increased the range of vector amount transfected in LNCaP and another AP2g negative line (PC3MM2); however, in spite of clearly detecting expressed AP2 in these lines, we never obtained any evidence for activation of the reporter by AP2g alone (data not shown). In transfections to examine the importance of heterodimer formation, AP2a again induced a small rise in reporter activity, but AP2g failed to activate the promoter (Figure 6g) . Interestingly, when cotransfected, the presence of AP2g inhibited activation by AP2a. Similarly, transfection of AP2b alone induced a 2.3-fold induction of promoter activity (Figure 6h ), but this was inhibited (activation reduced to 1.5-fold) by cotransfection with AP2g. We suggest that these data support the idea that AP2a/g and AP2b/g are the functionally important AP2 species contributing to KAI1 reporter Together, these results confirmed the possible importance of a synergistic interaction between p53 and junB to KAI1 promoter activity, and that AP2 (specifically heterodimers of AP2a/g and AP2b/g) might contribute low level promoter activation.
Discussion
An investigation of regulatory elements within the human KAI1 gene promoter (Marreiros et al., 2003) identified a 76 bp promoter element (À922 to À847 bp upstream of the transcription initiation site) essential for high level promoter activity in bladder cancer cells, and which contained binding motifs for AP2, p53 and AP1. In the present study, we have shown the importance of this regulatory element for high level promoter activity in transformed prostate and prostate cancer cell lines. We have also identified specific AP2 and AP1 proteins binding this promoter region, and provided evidence for an essential requirement for binding of p53 and junB to KAI1 promoter activity, and a synergistic interaction between these two proteins. In addition, we show that heterodimers of AP2a/AP2g and AP2b/AP2g may contribute to highest levels of promoter activity (summarized in Figure 7 ). This requirement for three different transcription factors may explain why in recent studies, a direct relationship between loss of p53 function and reduced expression of KAI1 has been difficult to demonstrate (initially reviewed in Jackson and Puisieux, 2000; Jackson et al., 2002 Jackson et al., , 2003 .
Previously, we showed that binding of AP1 was essential for KAI1 promoter activity in bladder cancer cells, but that reduced levels of total AP1 protein did not correlate with downregulation of KAI1 mRNA (Marreiros et al., 2003) . In this study, we provided experimental evidence for junB as the critical AP1 protein in regulating KAI1 transcription. Among AP1 proteins, and consistent with our data, JunB is a weak activator of transcription (for example, Vandel et al., 1996) , but can play an important role in limiting cell proliferation (reviewed in Shaulian and Karin, 2002) by forming heterodimers with c-jun, and acting as an antagonist to c-jun-dependent upregulation (for example, Cyclin D1 and GM-CSF), or downregulation (for example, p16) of genes associated with cell proliferation. Our data also provided evidence for a synergistic functional interaction between p53 and junB under certain conditions, which acted to enhance low level promoter activation induced by each factor alone. Functional interactions between p53 and AP1 have been suggested from data in a previous study. Induction of KAI1 mRNA in A549 prostate cancer cells exposed to etoposide was shown to require p53 and the c-jun component of AP1 (Mashimo et al., 2000) , although in this system, levels of promoter activation did not suggest any additive or cooperative effects. Furthermore, the authors were unable to identify a region within the KAI1 promoter to which c-jun was specifically binding. The importance of AP2 to progression of melanoma and cancers of the breast, colon and prostate has been attributed to AP2a-dependent regulation of key genes. A loss of AP2a results in decreased levels of c-kit , and upregulation of MUC-18 , PAR-1 (Tellez and Bar-Eli, 2003) or VEGF (Ruiz et al., 2004) , all associated with increased tumourigenic and metastatic abilities Jean et al., 1998; Ruiz et al., 2004) . Our studies have suggested that AP2 also contributes to regulation of KAI1 expression and from a combination of gel shift analyses and transfections, suggested that the functionally relevant AP2 species was not AP2a alone, but heterodimers of AP2a and AP2b with AP2g. Evidence for specific roles of AP2b and AP2g in regulating expression of cancer-related genes is limited. However, AP2g but not AP2a or AP2b activates the ErbB-3 promoter (Zhu and Domann, 2002) , and both AP2b and AP2g (as well as AP2a) can bind the c-erbB-2 promoter, although in reporter assays AP2a and AP2g are 3-4-fold more effective then AP2b (Bosher et al., 1996) . Transcription from the c-erbB-2 promoter is regulated by a critical element containing AP2-binding motifs. In breast cancer cell lines overexpressing c-erbB-2, there is overexpression of AP2a and AP2g but not AP2b (Bosher et al., 1996) , suggesting that altered expression of individual AP2 proteins may be important in determining levels of transcription from genes regulated by AP2. Interestingly, evidence has recently been obtained for a direct interaction between p53 and both AP2a and AP2g (McPherson et al., 2002) . This interaction resulted in AP2a being directed to p53-binding motifs in a target gene (p21/WAF1), resulting in augmentation of the ability of p53 to transactivate the gene. In contrast to our data, however, this study did not demonstrate any direct transcriptional activation by AP2a alone.
To provide support for the importance of p53, junB and AP2 proteins to endogenous KAI1 mRNA expression more generally, we examined levels of these proteins by Western analysis, in nuclear extracts from different prostate cancer cell lines, in which KAI1 mRNA levels varied widely. These data showed that major downregulation of KAI1 mRNA levels could be explained by a loss of p53 function or loss of junB expression, combined with an absence of AP2a, AP2b or AP2g. Conceivably, these data may be confined to cells in culture, and an important future direction of future investigation will be to examine p53, junB and AP2 protein expression in tumour tissue samples showing downregulation of KAI1 expression. However, our data provide the basis of a plausible model, whereby altered expression of three key transcription factors might be a possible mechanism responsible for reduction of KAI1 expression in invasive and metastatic tumour cells.
Materials and methods
KAI1 reporter plasmids
Reporter plasmids p-2900KAICAT, p-1118KAICAT and p-846KAICAT were from Dr K Watabe (Department of Medical Microbiology and Immunology, Southern Illinois University; Mashimo et al., 1998) . Construction of p-1069KAICAT, p-892KAICAT and p-922KAICAT, using a PCR-based approach and pBLCAT3 as the vector backbone, has been detailed previously (Marreiros et al., 2003) . A transfection control, pRcCMVCAT (with the human CMV promoter controlling a bacterial CAT gene), was from Dr R Reddel (Children's Medical Research Institute, Westmead, NSW, Australia).
Site-directed mutagenesis
Reporter plasmids with mutations in individual AP2-, p53-or AP1-binding motifs, or with combinations of mutations in these motifs, were made by a PCR approach using mismatched primers listed in Table 2 , and KAI1 reporter plasmid templates whose construction has been described previously (Table 2 ; Marreiros et al., 2003) . Amplification of all promoter sequences used a common reverse primer (Table 2) and Taq polymerase. Each reaction included 5.0 ml 10Â reaction buffer, 0.5 ml of 25mM dNTP mix, 50 ng DNA template, 50 pmol of each primer, 0.5 ml enzyme and 2.0 ml 25 mM MgCl 2 , Construction of these KAI1 reporters with already mutated motifs is described in detail (Marreiros et al., 2003) . Nucleotides underlined denote residues changed from normal sequence in promoter Dong et al., 1997; Mashimo et al., 1998) upstream of the bacterial CAT gene. Correct insertion of each promoter fragment and introduction of specific mutations were verified by restriction enzyme digestion and direct sequencing of the full promoter sequence in 5 0 -3 0 and 3 0 -5 0 directions using two different primer combinations. This approach yielded plasmids, p922KAI1mutAP2 (mutation in the AP2-binding motif between promoter residues À907 to À899), p922KAI1mutp53 (mutation in the p53-binding motif between À891 to À867), p922KAI1mutAP1 (mutation in the AP1-binding motif between promoter residues À866 to À860), pKAImutP (mutations in AP2-, p53-and AP1-binding motifs), pKAImutQ (mutations in AP2-and p53-binding motifs only), pKAImutR (mutations in AP2-and AP1-binding motifs only) and pKAImutS (mutations in p53-and AP1-binding motifs only). All plasmids are schematically illustrated in Figure 4 .
Cell culture and transfections
Prostate cancer cell lines DU145 (HTB-81) and PC3 (CRL-1435), and the HPV-transformed prostate cell line PZ-HPV-7 (CRL-2221) were from the American Type Culture Collection. LNCaP were from Lelund Chung (Department of Urology, Emory University School of Medicine, Atlanta, GA, USA) and LNCaP derivatives LNCaP-C4 and LNCaP C4-2 were from UroCor (Oklahoma City, OK, USA). PC3 derivatives, PC3M and PC3MM2, were from Dr I Fidler (MD Anderson Cancer Center, Houston, TX, USA). MDA-PCa-2A and MDA-PCa-2B were from Dr N Navone (MD Anderson Cancer Center, Houston, TX, USA). All lines were cultured under conditions previously described (Jackson et al., 2002) .
In reporter experiments, cells were seeded into 6 cm culture dishes (10 6 cells/dish, PZ-HPV7 and 5 Â 10 5 cells/dish, all other cells) and 24 h later transfected with reporter DNA and DOTAP liposomal transfection reagent (Roche Diagnostics, Castle Hill, NSW, Australia) as previously optimized (Jackson et al., 2002) . For each cell type, the DNA/lipid complex was removed after 5 h, and incubation continued in fresh complete medium. Cells were harvested 24 h (or 48 h for PZ-HPV-7) after DNA addition, and CAT activity in cell lysates containing equal amounts of protein measured as described (Yardley et al., 1998) . Unless otherwise indicated, results illustrated are means with standard error of at least three independent experiments, each performed in duplicate.
In cotransfections, LNCaP cells were transfected with 1.0 mg of p-922KAICAT reporter and expression vectors as indicated. In all experiments, the empty vector was used to ensure amounts of total transfected DNA remained constant at 3.0 mg. Plasmid pRcCMVp53WT (expressing wtp53 from a CMV promoter) was from Dr Roger Reddel (Children's Medical Research Institute, Westmead, NSW, Australia). An empty vector control, pRcCMV, was generated by digestion of pRcCMVp53WT with XbaI, to remove p53 sequence, and religation of remaining DNA. Plasmid pSG5junB (expressing human junB from the SV40 promoter; Bergman et al., 2003) and control vector pSG5 were from Dr David Lovett (Department of Medicine, San Francisco Veterans Affairs Medical Center). Plasmids pcDNA-AP2a and pcDNA-AP2g expressing AP2a and AP2g, respectively, from a CMV promoter; McPherson and Weigal, 1999) and control vector pcDNA3.1 þ were from Dr Ron Weigal (Department of Surgery, Thomas Jefferson University, Philadelphia, PA, USA). Plasmids pRSV-AP2b (expressing human AP2b from an RSV promoter; Bosher et al., 1996) and control vector pRSV were from Dr Helen Hurst, Molecular Oncology Unit, ICSM, Hammersmith Hospital, London, UK).
RT-PCR analysis of KAI1 expression
Total RNA was isolated from cell cultures when 80-90% confluent using TriReagent (Sigma-Aldrich Pty Ltd, Castle Hill, NSW, Australia) as per the manufacturer's instructions. After phenol/chloroform extraction to remove residual DNA, 2 mg RNA was used to prepare cDNA as described . In each PCR reaction, 2 ml of cDNA was used. A 1030 bp KAI1 mRNA fragment was amplified using forward, 5 0 -AGTCCTCCCTGCTGCTGTGTG-3 0 and reverse, 5 0 -TCAGTCAGGGTGGG-CAAGAGG-3 0 primers, respectively. As control for RNA integrity and loading into cDNA reactions, a 600 bp GAPDH fragment was amplified using primers 5 0 -CCACCCATGGCAAATTCCATGGCA-3 0 and 5 0 -TCTAGACGGCAGGTCAGGTCCACC-3 0 . Amplification with each primer set was achieved in a Hybaid Touchdown Thermocycler using an initial step of 941C 4 min, followed by 21 cycles (GAPDH) or 27, 31, 35 cycles (KAI1) of 941C 30 s, 601C 30 s and 721C 90 s, with a final step of 72 0 C 10 min. Reaction products were separated in 1.5% agarose gels, visualized with ethidium bromide and analysed by Kodak Digital Science 1D Image Analysis Software.
Electromobility shift assays (EMSA)
Nuclear extracts from PZ-HPV-7 cells were prepared as below, aliquoted and stored at À801C. Single-stranded, complementary oligonucleotide sequences corresponding to individual promoter AP2-, AP1-and p53-binding motifs, as well as sequences with mutations in each motif (Figure 3) , were from Sigma-Aldrich (Castle Hill, NSW, Australia) and annealed to form double-stranded probes. Unlabelled consensus AP2, AP1, p53 motif double-stranded oligonucleotides (1.44pmol/ ml) were from Santa Cruz (Santa Cruz, CA, USA). AP2 (sc-184X), AP1 (sc-44X), and p53 (sc-126X) antibodies, and antibodies specific for individual components of AP1 (c-fos, sc-53X; Fos B, sc-48X; Fra-1, sc-605X; Fra-2, sc-171X; c-Jun, sc-45X; jun B, sc-73X; Jun D, sc-74X), ATF/CREB (ATF-1, sc-243X; ATF-2, sc-187X; ATF-3, sc-188X; CREB-1, sc-240X; CREB-2, sc-200X; CREM-1, sc-440X) or AP2 (AP2a, sc-8975X; AP2b, sc-8976X and AP2g, sc-8977X) were from Santa Cruz (Santa Cruz, CA, USA). Radioactive probes were generated by labelling a single-stranded promoter oligonucleotide with T4 polynucleotide kinase (New England Biolabs, Beverly, MA, USA) and [g-32 P]dATP (Bresagen, 3000 Ci/ mmol), annealing the complementary oligonucleotide and purification through a Sephadex G25 Quickspin column (Roche Molecular Biochemicals, Indianapolis, IN, USA). Binding assays were performed for 10 min on ice using 2 ml of nuclear extract (6-10 mg total protein) in 30 ml reactions containing binding buffer (10 mM HEPES pH 7.8, 50 mM KCl, 5 mM MgCl 2 , 1 mM EDTA, 5% glycerol), 1 mM DTT, 0.25 mg poly[dI:dC] and 0.2 ml radiolabelled probe (13 fmol; >30 000 c.p.m./ml). In competition experiments, cold competitor (50 Â molar excess) was included with the nuclear extract for 10 min prior to addition of labelled probe. In supershift experiments, 4 ml of antibody (2 mg/ml) was incubated with the nuclear extract for 3 h at 41C after probe addition. Complexes were separated in 6% nondenaturing polyacrylamide gels (0.25 Â TBE) at 250 V for 90 min at 41C. All gels were dried and examined by Phosphoimage analysis.
Western blotting
Nuclear extracts were prepared by the Pierce NE-Per system (Pierce Endogen, Rockford, IL,USA) as described by the manufacturer. Protein concentrations were determined by BCA assay (Pierce Endogen, Rockford, IL, USA). Extracts, containing 10 mg of protein, were separated in 10% SDSpolyacrylamide gels and transferred to nitrocellulose membranes. After blocking with PBSTM (0.1% Tween-20 in PBS, PBST, containing 5% skimmed milk) for 1 h at room temperature, filters were probed overnight at 41C with antibodies described above. After rinsing in PBST (3 Â 5 min), filters were incubated with a 1/5000 dilution in PBSTM, of an appropriate HRP-linked secondary antibody, for 1 h at room temperature. After final rinsing with PBST (3 Â 5 min) to remove unbound antibody, specific proteins were visualized by the enhanced chemiluminescence (ECL) method (Amersham Biosciences, Castle Hill, NSW, Australia) and exposure to Kodak Xomat film.
